FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

Matthias R. Benz; Johannes Czernin; William D. Tap; Jeffrey J. Eckardt; Leanne L. Seeger; Martin S. Allen-Auerbach; Sarah M. Dry; Michael E. Phelps; Wolfgang A. Weber; Fritz C. Eilber

doi:10.1155/2010/143540

Sarcoma (Jan 2010)

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

Matthias R. Benz,
Johannes Czernin,
William D. Tap,
Jeffrey J. Eckardt,
Leanne L. Seeger,
Martin S. Allen-Auerbach,
Sarah M. Dry,
Michael E. Phelps,
Wolfgang A. Weber,
Fritz C. Eilber

Affiliations

Matthias R. Benz: Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Johannes Czernin: Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
William D. Tap: Division of Medical Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Jeffrey J. Eckardt: Department of Orthopedic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Leanne L. Seeger: Department of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Martin S. Allen-Auerbach: Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Sarah M. Dry: Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Michael E. Phelps: Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
Wolfgang A. Weber: Abteilung Nuklearmedizin, University of Freiburg, 79106 Freiburg, Germany
Fritz C. Eilber: Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA

DOI: https://doi.org/10.1155/2010/143540
Journal volume & issue: Vol. 2010

Abstract

Read online

Purpose. The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic response to neoadjuvant treatment in adult patients with primary bone sarcomas. Methods. Twelve consecutive patients with resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the initiation and after completion of neoadjuvant treatment. Imaging findings were correlated with histopathologic response. Results. Histopathologic responders showed significantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow up than non-responders (64±19% versus 29±30 %, resp.; P=.03). Using a 60% decrease in tumor FDG-uptake as a threshold for metabolic response correctly classified 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic responders and non-responders, respectively (sensitivity, 75%; specificity, 88%). Conclusion. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients.

Published in Sarcoma

ISSN: 1357-714X (Print); 1369-1643 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/5805

About the journal